close

Transition Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications. Its lead products include ELND-005/AZD-103, a Phase II clinical trial product for the treatment of Alzheimer's disease; and TT-223 gastrin analogue, a Phase II clinical trial product for the treatment of diabetes. The company's TT-223 gastrin analogue, includes TT-223 in combination with a GLP-1 analogue as a therapy for the treatment of type 1 and type 2 diabetes, which is under clinical development; and TT-223 in combination with EGF analogues that has completed two Phase I clinical trials for the drug candidate in type 1 and type 2 diabetics. In addition, Transition Therapeutics has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. It has a strategic collaboration with Elan Pharma International Limited to develop and commercialize ELND-005/AZD-103 therapeutic agent, as well as a licensing and collaboration agreement with Eli Lilly and Company to develop and commercialize gastrin based therapies, including the lead compound TT-223. The company, formerly known as Transition Therapeutics and Diagnostics, Inc., was founded in 1987 and is based in Toronto, Canada.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.85
Volume	23499
Volume Avg	46688
52 Week High	5.04
52 Week Low	1.15
PE	9.49
PE (group average)	N/A
EPS Year	0.20
EPS change Q/Q	-1000%
EPS change Q/Q Yr ago	-1000%
EPS change Q/Q next Q est	-1000%
EPS change Y/Y	1000%
REV change Q/Q	-100%
REV change Q/Q Yr ago	3030%
EPS next Q est	-0.25
EPS next Y est	-0.85
Divident Annual	0.00
Dividend Yield	0%